Grandise (Granisetron Hydrochloride)

Granisetron is primarily approved for chemotherapy‑induced and postoperative nausea and vomiting; use for radiation‑induced nausea should be considered off‑label and discussed with a healthcare professional.

No, Grandise is a prescription‑only medication (Rx) in the EU and must be prescribed by a qualified healthcare provider.

Grandise is taken orally, usually 30 minutes before the start of chemotherapy or surgery, as directed by the prescribing clinician.

Common side effects include headache, constipation, fatigue, dizziness, and mild diarrhea.

Serious reactions, though rare, can include severe allergic responses, cardiac arrhythmias, QT interval prolongation, and serotonin syndrome when combined with serotonergic drugs.

Patients with known QT prolongation or other cardiac rhythm disorders should be evaluated carefully, and alternative antiemetics may be preferred.

Granisetron can be part of a multimodal regimen, but duplicate therapy with another 5‑HT3 antagonist should be avoided.

Clinicians may monitor ECG for QT changes, assess liver function in hepatic impairment, and watch for signs of hypersensitivity during the initial treatment period.

Safety data in pregnancy and lactation are limited; the medication should only be used if the potential benefit justifies the potential risk, after consulting a healthcare professional.

Severe renal dysfunction may require dose adjustment or alternative therapy, as granisetron is primarily eliminated unchanged by the kidneys.

If a dose is missed, the patient should take it as soon as they remember unless the next scheduled dose is near; they should not double the dose and should follow the prescriber's instructions.